BioLife Sciences Inc.
BLFE · OTC
2/28/2022 | 8/31/2021 | 5/31/2021 | 2/28/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $135 | $126 | $57 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $135 | $126 | $57 |
| Operating Income | -$0 | -$135 | -$126 | -$57 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$8 | -$12 | -$10 |
| Pre-Tax Income | -$0 | -$143 | -$138 | -$67 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$143 | -$138 | -$67 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.005 | -0.003 | -0.001 |
| % Growth | 100% | -108% | -108.3% | – |
| EPS Diluted | -0.002 | -0.003 | -0.003 | -0.001 |
| Weighted Avg Shares Out | 54,890 | 54,890 | 54,890 | 54,864 |
| Weighted Avg Shares Out Dil | 54,890 | 54,890 | 54,890 | 54,864 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $8 | $12 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$135 | -$126 | -$58 |
| % Margin | – | – | – | – |